Cassava Announces Closure of U.S. Department of Justice Investigation
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.
As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC’s allegations.
The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.
“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” said Richard J. Barry, President and Chief Executive Officer of Cassava.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications.
For more information, please visit: https://www.CassavaSciences.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Strategy’s STRC plan could bring 365 dividend record dates – Details
Brazil’s New Crypto Rules Could Change the Market: 5 Altcoins Worth Holding as October Nears
With Q3 financial reports approaching, Samsung Electronics and SK Hynix face "extremely high expectations," testing "global AI trading"
The AI wave is driving a global semiconductor "super cycle," with combined third-quarter operating profits of Samsung and SK Hynix potentially approaching the historical record of 190 trillion won. The competition for HBM4 is intensifying, as agent-based AI pushes storage bandwidth demand up tenfold, making memory truly the "lifeblood" of AI data centers. Two upcoming financial reports will determine whether this boom is merely a flash in the pan or a structural transformation that will reshape the foundation of technology infrastructure.

‘Provide future qualification path’ — Strive challenges MSCI proposal to exclude Bitcoin treasuries
